CSL Statutory Accounts for FY2026
Filed with ASX · · 175 pages · English
Summary by 6ix AI
The report highlights a substantial net loss attributable to members of the parent entity, driven by restructuring activities and impairments. Despite the loss, total revenue showed a slight increase compared to the previous year, indicating resilience in core markets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CSL
- European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries
- CSL Update on Enhanced Plasma Manufacturing
- CSL Marks the Completion of the First Vessel in World-Leading Transhipment Fleet for Simandou Project
- CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
- CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations
Later from CSL
- CSL FY2026 Results
- CSL Results Presentation for FY2026
- World’s-First Battery-Powered Self-Unloading Bulk Carrier Now Operating in South Australia
- CSL Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing
- Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Follow CSL into a list and get an email when it puts out news.
Follow CSL